Evidence map›Paper›PMID 41714320›Full record

ArticleCell death & disease2026

mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR

Luise von Wichert, Alina Stroh, Marie Witt, Michael Wanzel, Marco Mernberger, Sebastian Griewing, Thomas Wündisch, Berit M Pfitzner, Julia Teply-Szymanski, Anne-Sophie Litmeyer and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Luise von WichertInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.ORCID http://orcid.org/0009-0006-0647-1235
Alina StrohInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Marie WittInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.ORCID http://orcid.org/0009-0003-4836-8605
Michael WanzelInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Marco MernbergerInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Sebastian GriewingDepartment of Gynecology, Gynecological Endocrinology and Oncology, University Hospital Marburg (UKGM), Philipps-University, Marburg, Germany.
Thomas WündischComprehensive Cancer Center Marburg, University Hospital Marburg (UKGM), Philipps-University, Marburg, Germany.
Berit M PfitznerInstitute of Pathology, DRK Clinics Westend, Berlin, Germany.
Julia Teply-SzymanskiInstitute of Pathology, University Hospital Marburg (UKGM), Philipps-University, Marburg, Germany.ORCID http://orcid.org/0000-0002-3880-1968
Anne-Sophie LitmeyerInstitute of Pathology, University Hospital Marburg (UKGM), Philipps-University, Marburg, Germany.
Carsten DenkertInstitute of Pathology, University Hospital Marburg (UKGM), Philipps-University, Marburg, Germany.
Uwe WagnerDepartment of Gynecology, Gynecological Endocrinology and Oncology, University Hospital Marburg (UKGM), Philipps-University, Marburg, Germany.
Thorsten StieweInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.ORCID http://orcid.org/0000-0003-0134-7826
Niklas GremkeInstitute of Molecular Oncology, Universities of Gießen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany. Gremken@staff.uni-marburg.de.ORCID http://orcid.org/0000-0002-9015-3646

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) GRK 2573/2 - 2024Uniklinikum Giessen und Marburg (University Hospital Giessen and Marburg) Grant 3/2022 MR
6 · The paper itself

Abstract

Breast cancer (BC) is the most prevalent malignancy in women, with hormone receptor-positive, HER2-negative (HR

Indexed as

AutophagyBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsTOR Serine-Threonine KinasesAminopyridinesAnimalsCell Line, TumorFemaleHumansMechanistic Target of Rapamycin Complex 1Metabolic ReprogrammingMiceAminopyridinesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMechanistic Target of Rapamycin Complex 1MTOR protein, humanpalbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesribociclibTOR Serine-Threonine Kinases

Identifiers

PMID41714320
PMCPMC12948975

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.